RxDoctor Payments Data

Katherine Crotwell

Family · Baton Rouge, LANPI 1992156434

Payments from drug & device makers

$2,164in general payments, 2019–2025

Across 66 payments — averaging $32.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$755
  • Takeda Pharmaceuticals U.S.A., Inc.$278
  • Baxter Healthcare$199
  • Solventum Corporation$150
  • Coloplast$128
  • Braintree Laboratories, Inc.$125
  • plus $529 from 10 others

What the payments were for

  • Travel & lodging$2009%
  • Food & beverage$1,92889%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,164 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,216
Medicare patients
37
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates482$32,717
LinzessLinaclotide25$12,719
ClenpiqSod Picosulf/Mag Ox/Citric Ac16$2,681
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag13$1,617
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$451
Neomycin Sulfate13$77
Ondansetron OdtOndansetron14$77
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$73
Tramadol Hcl31$63
Oxycodone Hcl14$53
Metronidazole20$53
Diazepam17$36
Amitriptyline Hcl12$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$18$2,68116 claims
Braintree Laboratories, Inc.Suflave$125$1,61713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.

Other family in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →